- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| Fr | JPM Raises SKB BIO TP to HKD648 as Company Research Achieves Positive Results | 1 | AASTOCKS | ||
| Do | Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy | 1 | Pharmaceutical Technology | ||
| Mi | Kelun scores sac-TMT win in first-line NSCLC population missing from Merck's massive phase 3 program | 4 | FiercePharma | ||
| Mi | Kelun Biotech, Harbour BioMed Get China Approval For IND Application Of Asthma Drug; Shares Up | 2 | RTTNews | ||
| Mi | G Sachs: SKB BIO sac-TMT Combination Therapy Clinical Study Meets Primary Endpoint, Maintains Buy Rating | 3 | AASTOCKS | ||
| Mi | Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint | 64 | PR Newswire | As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06... ► Artikel lesen | |
| Mi | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT PRIMARY ENDPOINT MET FOR PHASE 3 STUDY OF CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN COMBINATION ... | 1 | HKEx | ||
| 10.07. | SKB BIO (06990): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.07. | SKB BIO (06990): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 10.07. | SKB BIO (06990): (1) COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 08.07. | Sichuan Kelun Biotech Aktie bricht nach Aktienplatzierung mit hohem Abschlag ein | 1 | Investing.com Deutsch | ||
| 08.07. | SKB BIO Places Shares at 8.5% Discount, Raises Net Proceeds of HKD2.7B+ | 1 | AASTOCKS | ||
| 08.07. | SKB BIO (06990): (1) PLACING OF NEW H SHARES UNDER GENERAL MANDATE; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 07.07. | SKB BIO (06990): RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORIZED REPRESENTATIVE | 1 | HKEx | ||
| 30.06. | SKB BIO (06990): DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 29.06. | SKB BIO (06990): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2026 | - | HKEx | ||
| 22.06. | Kelun-Biotech: Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell | 202 | PR Newswire | - The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.- The Company is conducting a Phase III registrational... ► Artikel lesen | |
| 12.06. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT RECEIPT OF PAYMENT MADE BY MEDILINK THERAPEUTICS PURSUANT TO THE SETTLEMENT | - | HKEx | ||
| 09.06. | Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378 | 219 | PR Newswire | COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease
SKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS... ► Artikel lesen | |
| 04.06. | SKB BIO (06990): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 29, 2026 | 1 | HKEx |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,19 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,300 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,12 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 18,810 | -0,05 % | Erasca closes $632.5 million public stock offering | ||
| TARSUS PHARMACEUTICALS | 56,33 | +0,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,455 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,310 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,765 | -0,03 % | BMO initiates Trevi Therapeutics stock at Outperform, $36 target | ||
| HEMAB THERAPEUTICS | 49,390 | 0,00 % | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | ||
| KYMERA THERAPEUTICS | 111,11 | +0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,26 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| QIAGEN | 35,050 | -2,69 % | Evotec, Formycon oder Qiagen? Diese Aktie kann sich jetzt verdoppeln | Der europäische Biotech-Sektor bleibt in Bewegung: Unternehmensnachrichten, Partnerschaften und Analysteneinschätzungen sorgen derzeit für teils deutliche Kursausschläge. Bei Evotec, Formycon und Qiagen... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,800 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen | |
| VOR BIOPHARMA | 17,450 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,230 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen |
Das Unternehmen SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.